Engineered Extracellular Vesicles for Let-7i-5p Delivery in ARDS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute respiratory distress syndrome (ARDS) are limited, with high mortality and a lack of effective therapeutic modalities, focusing mainly on supportive care rather than direct intervention.
Innovation Solution
A pharmaceutical composition comprising extracellular vesicles engineered to carry let-7i-5p miRNA, derived from animal cells such as macrophages, is developed to reduce lung injury and inflammation by administering the vesicles to subjects in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If supportive care is provided for ARDS patients, then basic respiratory support is maintained, but effective therapeutic intervention is insufficient
Solution Approach 1:
The patent uses extracellular vesicles as intermediary carriers to deliver let-7i-5p miRNA to lung tissue. These vesicles serve as a bridge between the administered miRNA and the target cells, enabling effective therapeutic intervention by facilitating the delivery and functional expression of the miRNA in the lung microenvironment.
Solution Approach 2:
The patent modifies the natural state of extracellular vesicles by engineering them to specifically carry and express let-7i-5p miRNA. This parameter change transforms ordinary supportive care into targeted therapeutic intervention, as the engineered vesicles actively modulate lung injury pathways rather than merely providing passive support.
2Use of energy by moving object
If mechanical ventilation is used for ARDS patients, then oxygen delivery is increased, but lung injury and inflammation are exacerbated
Solution Approach 1:
The patent converts the harmful effects of mechanical ventilation and lung injury into beneficial outcomes by using the stress-induced expression of let-7i-5p miRNA as a therapeutic mechanism. The miRNA is engineered to counteract the inflammatory pathways activated during ventilation, transforming the harmful mechanical stress response into a protective therapeutic effect.
Solution Approach 2:
The patent employs preliminary action by pre-engineering extracellular vesicles to carry let-7i-5p miRNA before administration. This preliminary preparation ensures that the therapeutic miRNA is ready to immediately counteract lung injury mechanisms when delivered to the patient, rather than requiring post-injury adaptation or synthesis.
3Quantity of substance
If diuretics are administered to reduce fluid overload, then shunt fraction is reduced, but kidney function and electrolyte balance are compromised
Solution Approach 1:
The patent uses engineered extracellular vesicles as intermediaries to deliver let-7i-5p miRNA that regulates fluid handling in the lung. This approach specifically targets lung fluid dynamics without requiring system-wide diuretic intervention, thereby reducing fluid overload in the lungs while preserving kidney function and electrolyte balance.
Solution Approach 2:
The patent applies local quality by targeting the therapeutic effect specifically to the lung tissue through lung-enriched extracellular vesicles. This localized delivery of let-7i-5p miRNA regulates fluid handling only in the lung microenvironment, avoiding the systemic side effects of traditional diuretics on kidneys and electrolytes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces lung injury, inflammation, apoptosis, and improves lung function by increasing inspiratory capacity and reducing airway resistance, providing a potential therapeutic option for ARDS.
Implementation Method 1
the extracellular vesicle undergoes electroporation, lipofection, sonication, or contact with calcium chloride to load the miRNA
Implementation Method 2
the extracellular vesicle undergoes electroporation, lipofection, sonication, or contact with calcium chloride to load the miRNA
Implementation Method 3
the extracellular vesicle undergoes electroporation, lipofection, sonication, or contact with calcium chloride to load the miRNA
Data Source
AI summary
Provided is a composition including an extracellular vesicle engineered to carry a payload. Also provided is a method for preventing or treating a lung disease by administering the composition.